Tags

Type your tag names separated by a space and hit enter

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.
bioRxiv. 2021 Jan 07B

Abstract

Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N501 and Y501 viruses.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Preprint

Language

eng

PubMed ID

33442691

Citation

Xie, Xuping, et al. "Neutralization of N501Y Mutant SARS-CoV-2 By BNT162b2 Vaccine-elicited Sera." BioRxiv : the Preprint Server for Biology, 2021.
Xie X, Zou J, Fontes-Garfias CR, et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. bioRxiv. 2021.
Xie, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., Menachery, V. D., Weaver, S., Dormitzer, P. R., & Shi, P. Y. (2021). Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. BioRxiv : the Preprint Server for Biology. https://doi.org/10.1101/2021.01.07.425740
Xie X, et al. Neutralization of N501Y Mutant SARS-CoV-2 By BNT162b2 Vaccine-elicited Sera. bioRxiv. 2021 Jan 7; PubMed PMID: 33442691.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. AU - Xie,Xuping, AU - Zou,Jing, AU - Fontes-Garfias,Camila R, AU - Xia,Hongjie, AU - Swanson,Kena A, AU - Cutler,Mark, AU - Cooper,David, AU - Menachery,Vineet D, AU - Weaver,Scott, AU - Dormitzer,Philip R, AU - Shi,Pei-Yong, Y1 - 2021/01/07/ PY - 2021/1/14/entrez PY - 2021/1/15/pubmed PY - 2021/1/15/medline JF - bioRxiv : the preprint server for biology JO - bioRxiv N2 - Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N501 and Y501 viruses. UR - https://www.unboundmedicine.com/medline/citation/33442691/full_citation L2 - https://doi.org/10.1101/2021.01.07.425740 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.